

Zydus Cadila and Eczacıbaşı, a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey

Ahmedabad, India, June 15,2016

Zydus Cadila, a global healthcare provider and Eczacıbaşı İlaç Pazarlama A.Ş. a leading healthcare company of Turkey have signed a strategic collaboration agreement to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and also paves the way for a long term strategic collaboration to produce and launch new products in the market.

The agreement was signed at the headquarters of Eczacıbaşı Holding located at Kanyon Ofis in Istanbul by Mr. Pankaj Patel, Chairman and Managing Director of Zydus Group, Dr. Sharvil Patel, Deputy Managing Director of Zydus Group and Mr. Bülent Eczacıbaşı, Chairman of Eczacıbaşı Holding, Dr. Erdal Karamercan, CEO of Eczacıbaşı Group, and Ms. Elif Çelik, Eczacıbaşı Healthcare Group President.

Speaking on the agreement, Mr. Pankaj Patel stated, “We are glad to partner with Eczacıbaşı, a leading group in the field of healthcare in Turkey, to make available biotech therapies for patients in Turkey. The long term agreement between both partners to enrich this collaboration through introduction of new products, will augur well for healthcare access beyond geographies.”

In his speech at the ceremony, Mr. Bülent Eczacıbaşı stated that as Eczacıbaşı Group, they believe that new collaborations enabling innovation and creating added value in the field of healthcare are very important and also said “Our target is to ensure that the important worldwide advances in the field of biotech products are simultaneously reflected and reach more people in our country, and think that Zydus is a very right partner in this regard”.

About Zydus Cadila

Headquartered in Ahmedabad, India, Zydus Cadila is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19000 people worldwide. The group has a strong research pipeline of NCEs, biologics and vaccines and has over 1200 scientists engaged in R & D and is dedicated to creating healthier communities globally. In 2013, the group was the first to identify and develop Lipaglyn™ (Saroglitazar) and launch India's first NCE in the market. In 2014, the group launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. As a leading healthcare provider, the group aims to become a global research based pharmaceutical company by 2020.

About biosimilars

Zydus is committed to increasing patient access to high-quality biosimilars at affordable costs. Utilising its scientific and manufacturing expertise over the last many years, Zydus has built one of the largest biosimilars pipelines in the industry. Zydus currently markets 8 biosimilars products in India and has 20 biosimilars in various stages of development.